Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Filings indexed 830 across all filing types
Latest filing 2023-05-18 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-05-18 English
FORM 10-Q
Interim / Quarterly Report Q1 2023
2023-05-15 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which includes two main items: Item 2.02 reporting the results of operations and financial condition via a press release and presentation, and Item 5.02 announcing a change in senior management (appointment of interim CEO). The document contains no full financial statements or detailed financial analysis itself but references a press release and presentation as exhibits. The presence of a management change announcement is significant. Given the dual nature, the primary content is the management change announcement (Item 5.02) and the financial results are only summarized and linked to external exhibits. According to the classification rules, a Form 8-K with management changes is best classified as Board/Management Information (MANG). The financial results announcement is not a full earnings release document but a notice within the 8-K. Therefore, the best fit is MANG with high confidence.
2023-05-15 English
FORM 4
Director's Dealing
2023-05-12 English
FORM 3
Director's Dealing
2023-05-12 English
FORM 4
Director's Dealing
2023-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.